EORTC-1333-GUCG/PEACE III Trial Statement
28 Jun 2024
EORTC is pleased to announce that the phase III EORTC-1333-GUCG/PEACE III trial database is locked. It reached data maturity for its primary endpoint (radiological progression free survival) and analysis has started. The findings will be presented at an upcoming medical meeting and discussed with regulatory authorities.
The phase III EORTC-1333-GUCG/PEACE III trial is a randomised multicentre phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.
This trial is supported by an investigator driven clinical trial agreement from Bayer HealthCare Pharmaceuticals and Astellas Pharma Europe.
ENDS
Related News
First Site Activated in EORTC RENALUT Clinical Trial on Metastatic Clear Cell Renal Cell Carcinoma
26 Feb 2026
New results and forthcoming trials presented at ESMO 2025 underline EORTC’s commitment to patient-centred research
21 Oct 2025
First Site Activated in EU-Funded DE-ESCALATE Clinical Trial on Advanced Metastatic Prostate Cancer
10 Jun 2025
EORTC in the spotlight at ASCO 2025
4 Jun 2025
EORTC’s presence at ASCO 2025
28 May 2025
New study confirms link between cancer patients’ quality of life and survival
1 Apr 2025
New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024
17 Sep 2024
Late Breaking Results from the EORTC 1333/PEACE III phase III trial
16 Sep 2024
EORTC-1333-GUCG/PEACE III trial endpoint reached
12 Jul 2024
Completion of Patient Recruitment for International TIGER Study
19 Dec 2022
